Back to top

Image: Bigstock

Baxter International Inc.

Read MoreHide Full Article

Baxter outperformed the industry in a year’s time. Strong demand for CRRT, injectable pharmaceuticals, U.S. IV solutions and peritoneal dialysis therapies is a positive. The strategic buyouts of RECOTHORM and PREVELEAK are noteworthy. Recently, the company got FDA approval for Spectrum IQ Infusion System. Baxter’s surgical portfolio is highly diversified with products available in above sixty countries. It includes exclusive products like FLOSEAL Hemostatic Matrix, TISSEEL Fibrin Sealant, COSEAL Surgical Sealant and VASCU-GUARD Patch among others. On the flip side, Baxter expects its pharmaceutical business to report flat revenues on a year-over-year basis in 2018 owing to stiff competition. Further, foreign currency headwinds have been dampening the company’s performance. Baxter’s cyclophosphamide performance over the last five years lacked luster. This pose threats to the Integrated Pharmacy Solutions franchise business.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Baxter International Inc. (BAX) - free report >>

Published in